RESEARCH ARTICLE

REVISED KIF5A and KLC1 expression in Alzheimer's disease: relationship and genetic influences [version 2; peer review: 2 approved, 1 approved with reservations]

Kelly Hares¹ , Scott Miners², Neil Scolding¹, Seth Love², Alastair Wilkins¹

¹Bristol Medical School: Translational Health Sciences, MS and Stem Cell Group, University of Bristol, Bristol, BS10 5NB, UK

²Bristol Medical School: Translational Health Sciences, Dementia Research Group, University of Bristol, Bristol, BS10 5NB, UK

v2 First published: 19 Feb 2019, 1:1
<https://doi.org/10.12688/amrcopenres.12861.1>
 Latest published: 26 Jun 2019, 1:1
<https://doi.org/10.12688/amrcopenres.12861.2>

Abstract

Background: Early disturbances in axonal transport, before the onset of gross neuropathology, occur in a spectrum of neurodegenerative diseases including Alzheimer's disease. Kinesin superfamily motor proteins (KIFs) are responsible for anterograde protein transport within the axon of various cellular cargoes, including synaptic and structural proteins. Dysregulated KIF expression has been associated with AD pathology and genetic polymorphisms within kinesin-light chain-1 (KLC1) have been linked to AD susceptibility. We examined the expression of KLC1 in AD, in relation to that of the KLC1 motor complex (KIF5A) and to susceptibility genotypes.

Methods: We analysed KLC1 and KIF5A gene and protein expression in midfrontal cortex from 47 AD and 39 control brains.

Results: We found that gene expression of both *KIF5A* and *KLC1* increased with Braak tangle stage (0-II vs III-IV and V-VI) but was not associated with significant change at the protein level. We found no effect of KLC1 SNPs on KIF5A or KLC1 expression but KIF5A SNPs that had previously been linked to susceptibility in multiple sclerosis were associated with reduced *KIF5A* mRNA expression in AD cortex.

Conclusions: Future *in vitro* and *in vivo* studies are required to understand the cause of upregulated KIF5A and KLC-1 gene expression in AD and any potential downstream consequences on pathogenesis, including any contribution of genetic polymorphisms within the KIF5A gene locus.

Keywords

Alzheimer's disease, axonal transport, KIF5A, kinesin light chain-1, single nucleotide polymorphism

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 26 Jun 2019	 view		
version 1 19 Feb 2019	 view	 view	 view

1. **Gustavo F. Gustavo** , INIMEC-CONICET-Universidad Nacional de Córdoba, Córdoba, Argentina
2. **Scott T. Brady** , University of Illinois at Chicago (UIC), Chicago, USA
3. **Elizabeth Gray**, University of Oxford, Oxford, UK

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Kelly Hares (kelly.hares@bristol.ac.uk)

Author roles: **Hares K:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation; **Miners S:** Formal Analysis, Investigation; **Scolding N:** Resources, Supervision; **Love S:** Supervision, Writing – Review & Editing; **Wilkins A:** Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by a pilot grant from BRACE (Bristol Research into Alzheimer's and Care of the Elderly). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2019 Hares K *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Hares K, Miners S, Scolding N *et al.* **KIF5A and KLC1 expression in Alzheimer's disease: relationship and genetic influences [version 2; peer review: 2 approved, 1 approved with reservations]** AMRC Open Research 2019, 1:1 <https://doi.org/10.12688/amrcopenres.12861.2>

First published: 19 Feb 2019, 1:1 <https://doi.org/10.12688/amrcopenres.12861.1>

REVISED Amendments from Version 1

The discussion and conclusions of the manuscript have been amended to be less speculative and a better reflection of the data presented.

See referee reports

Introduction

Over 90% of Alzheimer's disease (AD) cases are sporadic rather than attributable to a single gene mutation. In these cases, as for many other sporadic adult-onset neurodegenerative diseases, the pathological changes are likely to be caused by a combination of environmental and genetic factors that activate variably independent pathogenic pathways that increase neuronal vulnerability to damage and death¹. One major genetic risk factor for sporadic disease is the $\epsilon 4$ allele of *APOE*². Aside from *APOE*, genome-wide association studies (GWAS), have linked single nucleotide polymorphisms (SNPs) in over 20 genetic loci to AD susceptibility³.

A common theme across neurodegenerative diseases is alterations in neuronal connectivity that can give rise to clinical symptoms before neuronal loss^{4,5}. Targeting the processes responsible for the changes in neuronal connectivity is a key therapeutic aim, before consequential axonal loss and neuronal death cause irreversible disability in patients with neurodegenerative disease^{6,7}. A crucial step in this transition from potentially reversible to irreversible disease is the disruption in axonal delivery of membrane-bound organelles from the neuronal soma to the synapse. The development of such disruption has been recognised pathologically in brain tissue, including in AD⁸, by the formation of axonal swellings at an early stage in the disease process.

Kinesin superfamily motor proteins (KIFs) are responsible for most anterograde protein transport within the axon of various cellular cargoes, including synaptic and structural proteins⁹. There are at least 38 different neuronally-enriched KIFs which contain a conserved microtubule-binding domain and a motor domain at their amino (NH₂-) terminus, which hydrolyses ATP in order to generate motile forces to shift associated cargoes along the axon, via microtubule tracks¹⁰. The heterogeneous tail (COOH-terminal) domain of KIFs determines their cargo-binding specificity¹¹.

Early disturbances in axonal transport are a feature of several neurodegenerative diseases^{12–14}, and studies have linked KIF dysregulation to AD^{15,16}. Conventional kinesin member KIF5A transports several cargoes, including APP and β - and γ - secretases, by complexing with kinesin light chain-1 (KLC1). Some have demonstrated APP and β - and γ - secretases are among those transported but other studies have not replicated these findings^{17–20}. Deletion of the KLC1 subunit in mice leads to early selective axonal transport defects, resulting in a disorganised neuronal cytoskeleton with APP, neurofilament (NF) and hyperphosphorylated tau accumulation²¹. Mice transgenic for

human APP with mutations that cause familial AD develop abnormal axonal swellings positive for KLC1 and structural axonal component phosphorylated NF-H, long before AD pathology can be detected^{8,22}.

Single nucleotide polymorphisms (SNPs) in the region of the *KLC1* gene have been linked to AD susceptibility; in particular, *rs8702* has been shown to predict conversion of mild cognitive impairment (MCI) to AD^{16,23,24}. Our previous studies have shown that SNPs within the *KIF5A* gene locus, linked to multiple sclerosis (MS) susceptibility, influence KIF5A expression in post-mortem brain^{25,26}.

We and others have found KIF5A expression to be increased in post-mortem AD and PD tissue^{27,28}. KIF members show a degree of functional redundancy, such that more than one KIF may transport a specific cargo²⁹. We therefore suggested that KIF5A might be upregulated in AD as compensatory protective response to defects in other, interoperable, axonal transport proteins, facilitating the transport and clearance of aggregating cargoes in the cell body and axon. In support of this hypothesis, we showed that KIF5A levels in both MS and AD correlated inversely with the amount of cargo APP^{26,27}. KIF5A shares many cargoes with anterograde motor protein KIF1B, such as mitochondria and synaptic vesicle proteins, and it can transport cargoes without complexing to KLC1^{9,30}.

In this study we aimed to determine whether KLC1 levels are altered in AD, the relationship between the levels of KLC1 and KIF5A, and whether expression of KLC1 in the cerebral cortex is influenced by *KLC1* polymorphisms, which have been linked to AD susceptibility.

Methods

Study cohort

Samples of midfrontal cortex (Brodmann area 8; 500mg) were obtained from the South West Dementia Brain Bank (Bristol, UK), under the terms of South West - Central Bristol Research Ethics Committee approval no 08/H0106/28+5. Our previous studies indicated an influence of post-mortem delay (PMD) on mRNA and protein expression in brain tissue²⁷. Therefore, cases with a PMD >72 h were excluded from analysis. We studied 47 cases of AD (in which, AD neuropathological change was an adequate explanation of dementia, according to National Institute on Aging-Alzheimer's Association guidelines³¹), and 39 age-matched controls with no history of cognitive impairment (Table 1).

RNA and protein extraction

Both RNA and protein were extracted from each sample by use of the Paris™ Kit (ThermoFisher Scientific; AM1921), according to the manufacturer's instructions. Samples were weighed, divided into 2x 50 mg portions and placed in 2 ml homogenisation tubes, pre-filled with 5x 2.3 mm silica beads (Strattech Scientific; 11079125z-BSP) and 300 μ L of Paris™ kit lysis buffer, with the addition of Halt™ Protease and phosphatase inhibitor cocktail and 0.5M EDTA (1:100)

Table 1. Clinical characteristics of Alzheimer's disease and control patient cohort.

Patient ID	Age (yrs)	Sex (M/F)	Post-mortem delay (hrs)	Braak stage
C 1	62	M	4	0
C 2	95	F	46	0
C 3	78	F	24	2
C 4	64	M	12	2
C 5	64	M	16	0
C 6	90	M	45	2
C 7	64	M	23	2
C 8	77	M	55	1
C 9	78	M	12	2
C 10	73	M	36	2
C 11	88	F	62	2
C 12	88	F	72	0
C 13	93	F	18	2
C 14	88	F	28	2
C 15	82	M	30	2
C 16	84	M	48	3
C 17	90	M	48	2
C 18	75	M	48	2
C 19	89	F	15	2
C 20	73	M	33	1
C 21	69	M	66	2
C 22	73	F	59	1
C 23	83	F	24	2
C 24	82	M	3	2
C 25	79	M	24	-
C 26	43	F	12	-
C 27	84	F	17	1
C 28	82	F	37	2
C 29	78	M	48	1
C 30	82	M	56	2
C 31	76	M	23	2
C 32	91	F	60	2
C 33	77	M	10	3
C 34	75	M	6	3
C 35	78	M	21	-
C 36	93	F	53	3
C 37	90	M	5.5	2
C 38	90	F	67.25	1
C 39	83	M	47.75	2
Mean	80 (+/- 11)	-	34 (+/- 20)	-
AD 1	89	F	71	5
AD 2	78	F	9	5
AD 3	81	F	42	6
AD 4	91	F	37	4

Patient ID	Age (yrs)	Sex (M/F)	Post-mortem delay (hrs)	Braak stage
AD 5	77	F	43	4
AD 6	96	F	53	4
AD 7	87	F	67	5
AD 8	79	F	70	3
AD 9	81	M	29	4
AD 10	91	F	70	5
AD 11	78	F	35	6
AD 12	83	F	43	5
AD 13	70	F	25	6
AD 14	78	F	4	5
AD 15	69	M	48	5
AD 16	74	M	50	5
AD 17	80	F	21	5
AD 18	95	M	48	3
AD 19	89	F	4	6
AD 20	79	M	28	6
AD 21	85	M	66	6
AD 22	81	F	66	4
AD 23	80	M	31	6
AD 24	90	F	21	4
AD 25	57	F	24	5
AD 26	54	F	24	6
AD 27	84	F	20	5
AD 28	93	M	20	3
AD 29	80	M	5	6
AD 30	87	F	55	6
AD 31	74	M	24	5
AD 32	78	F	21	5
AD 33	89	F	39	5
AD 34	84	M	64	5
AD 35	73	F	38	5
AD 36	68	M	61	6
AD 37	83	M	48	5
AD 38	74	M	48	5
AD 39	78	M	49	6
AD 40	78	M	50	6
AD 41	85	M	50	6
AD 42	98	F	21	5
AD 43	83	F	32	6
AD 44	69	M	12	5
AD 45	87	F	28	6
AD 46	84	F	21	6
AD 47	84	F	22	5
Mean	81 (+/- 9)	-	37 (+/- 19)	-

Abbreviations: AD: Alzheimer's disease; C: control; F: female; hrs: hours; M: male; yrs: years.

(ThermoFisher Scientific; 78440). Samples were homogenised using a Precellys@24 automated homogeniser (Stretton Scientific). Samples were subsequently centrifuged (Sorvall ST 16R) at 10,000 xg for 2 min at 4°C and the soluble protein supernatant removed and stored at -80°C until required. The remaining homogenate was taken through the additional manufacturer's steps for extraction and elution of RNA, before storage at -80°C.

gDNA extraction

An approximately, 2 mm slice was taken from each brain sample and gDNA extracted using the TaqMan@ Sample-to-SNP™ Kit (ThermoFisher Scientific; 4403313). Cortex was placed in lysis buffer, briefly centrifuged and incubated for 3 min at 95°C, before addition of DNA stabilising solution. Samples were then stored at -20°C until use.

Complementary DNA (cDNA) generation

Extracted RNA was quantified using the Qubit@ RNA HS Assay Kit (ThermoFisher Scientific; Q32852) and Qubit@ 4.0 fluorometer (excitation 600-645 nm and emission 665-720 nm) (ThermoFisher Scientific; Q33226), according to the manufacturer's instructions. Quantified RNA samples were subsequently treated with recombinant RNase-free DNase I (10,000U; Sigma Aldrich; 4716728001) and 50 mM MgCl₂ solution (Bioline; BIO-37026) to remove any trace DNA. Treated RNA was diluted to achieve 100 ng/50 µL for reverse transcription into cDNA using the High Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific; 4368814), according to the manufacturer's instructions. 50 µL of reverse transcription mastermix was added to diluted RNA samples before thermal cycling on a StepOnePlus PCR system™ for cDNA generation. The cycling conditions were holding at 25°C for 10 min, 37°C for 120 min, followed by 85°C for 5 min. cDNA was stored at -80°C until use.

Quantitative real-time PCR (qPCR)

cDNA (2 ng/µL) was diluted to a final volume of 20 µL in TaqMan@ 2x Fast Advanced Master Mix (ThermoFisher Scientific; 4444557) and TaqMan@ gene expression probe solution (FAM-MGB dye-labelled, ThermoFisher Scientific) for *KIF5A* (Hs01007893_m1), *KLC1* (Hs00194316_m1) *RBFOX3* (Hs01370653_m1) and *GAPDH* (Hs02758991_g1). qPCR was performed on a StepOnePlus™ Real-Time PCR system with StepOne software v2.1 (ThermoFisher Scientific), on a FAST ramp speed, (Holding at 50°C for 2 min, 95°C for 2 min, cycling (x40) at 95°C for 1 s, followed by 60°C for 20 s). As the genes of interest are expressed predominantly neuronally, gene expression was calculated relative to that of a neuron-specific calibrator gene, encoding neuronal nuclear protein NeuN (*RBFOX3*), by the 2^{-ΔΔCt} method. In addition, *RBFOX3* levels were normalised to ubiquitous house-keeping gene *GAPDH* to assess any influence of PMD on gene expression.

Genotyping

Extracted gDNA was genotyped using qPCRBIO Genotyping Mix Hi-ROX (PCR Biosystems; PB20.42-05) and inventoried TaqMan@ SNP Genotyping Assays (ThermoFisher Scientific; 4351379) for *rs8702* (C__11467163_10), *rs8007903* (C__2169408_10), *rs12368653* (C__26237749_10) and *rs4646536*

(C__25623453_10) (proxy for *rs703842*), according to the manufacturer's instructions. Genotyping was performed on a StepOnePlus™ Real-Time PCR system with StepOne software v2.1 (ThermoFisher Scientific), on a FAST ramp speed (Holding at 60°C for 30 s, 95°C for 3 min, cycling (x40) at 95°C for 15 s, 60°C for 1 min, holding at 60°C for 30 s).

Western blot

Validation of primary antibody specificity for use in dot blot analysis was verified using western blot, as per previous studies²⁷. Protein homogenates were diluted 1:1 with Laemmli 2x sample buffer (Sigma-Aldrich Ltd; S3401) and heated to 95°C to denature the protein. Samples and BLUeye Prestained Protein Ladder (Geneflow; S6-0024) were loaded onto mini-PROTEAN TGX gels (4–20%) (Biorad; 456-1093) in a Mini-PROTEAN Tetra cell (Biorad; 1658004), filled with Tris/Glycine/SDS running buffer (Biorad; 161-0732). The gel was run at 150 V until the dye front reached the bottom of the gel, before protein transfer onto nitrocellulose membrane for 90 min at 350 mA. Membranes were blocked in 5% BSA/Tris-buffered saline-Tween 20 (TBS-T) or 5% milk/TBS-T, for 1 h at room temperature. Primary antibodies were reconstituted in membrane blocking solution (detailed in Table 2) and added overnight at 4°C. The primary antibodies used were: mouse anti-AβPP (ThermoFisher Scientific; 13-0200), mouse anti-GAPDH (Abcam; Ab9484), mouse anti-PHF-TAU (ThermoFisher Scientific UK; MN1020), rabbit anti-KIF5A (Sigma-Aldrich Ltd; HPA004469), rabbit anti-KLC1 (Abcam; Ab174273) and rabbit anti-NeuN (Abcam; Ab177487). Bound primary antibody was detected by incubation with HRP-conjugated secondary antibodies for 1 h at room temperature (as detailed in Table 2). Protein expression was visualised using a chemiluminescence Clarity™ Western ECL Substrate (Biorad; 1705060). Antibodies displayed bands relative to their reported molecular weight, as described on manufacturer data sheets (Figure 1).

Dot blot

Dot blot was performed using a Bio-Dot Microfiltration manifold (Biorad), according to the manufacturer's instructions. Nitrocellulose membrane was pre-soaked in 1x TBS and placed in the manifold, before addition of 100 µL of protein homogenate/well (diluted 1:200 with 1x TBS). After microfiltration for 90 min, the membrane was removed and placed in blocking antibody, before antibody incubation (Table 2), as per the western blot protocol. Protein expression was visualised on a Biorad Universal III Bioplex imager, using a chemiluminescence Clarity™ Western ECL Substrate (Biorad). Image Lab™ 5.0 software (Biorad) was used for densitometric protein analysis. Integrated density values were expressed relative to the neuronal nuclear protein NeuN. In addition, NeuN protein levels were normalised to ubiquitous protein GAPDH to study any effect of PMD on protein expression.

Enzyme-linked immunosorbent assay (ELISA)

AD frontal tissue (200 mg) was homogenised in TBS extraction buffer to obtain the soluble protein fraction and the protein pellet was homogenised in guanidine to obtain the insoluble fraction, as previously described^{27,32}. Sandwich ELISA was used

Table 2. Antibodies used for immunoblotting.

Antigen	Species	Blocking antibody	WB/DB concentration	Company	RRID	HRP-conjugated secondary	RRID
APP	Mouse monoclonal	5% milk/TBS-T	1:500	ThermoFisher Scientific; 13-0200	AB_2532993	Goat anti-mouse IgG 1:5000 Abcam; Ab6789	AB_955439
GAPDH	Mouse monoclonal	5% milk/TBS-T	1:5000	Merck; MAB374	AB_2107445		
PHF-Tau	Mouse monoclonal	5% BSA/TBS-T	1:500	ThermoFisher Scientific; MN1020	AB_223647	Goat anti-mouse IgG 1:10,000 Stratech; 115-035-146-JIR	AB_2307392
KIF5A	Rabbit polyclonal	5% milk/TBS-T	1:1000	Sigma-Aldrich; HPA004469;	AB_1079212	Goat anti-rabbit IgG 1:10,000 Abcam; ab7090	AB_955417
KLC1	Rabbit monoclonal	5% BSA/TBS-T	1:5000	Abcam; Ab174273	AB_2783556		
NeuN	Rabbit monoclonal	5% milk/TBS-T	1:5000	Abcam; Ab177487	AB_2532109		

Abbreviations: APP: amyloid precursor protein; BSA: bovine serum albumin; DB: dot blot; KIF: kinesin superfamily protein; KLC1: kinesin light chain-1; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; NeuN: neuronal nuclear protein; PHF: paired-helical filament; RRID: Research Resource Identifiers; T: TBS-T: tris-buffered saline-tween; WB: western blot.

Figure 1. Antibody specificity. western blots performed using AD protein homogenates, derived from mid-frontal cortex. Predicted molecular weight of APP 110-135kDa. Antibody used for detection was mouse anti-APP (1:2000), ThermoFisher Scientific; 13-0200 (**A**). Predicted molecular weight of GAPDH 37kDa. Antibody used for detection was mouse anti-GAPDH (1:5000), Merck; MAB374 (**B**). Predicted molecular weight of KIF5A 107kDa and 117kDa. Antibody used for band detection was rabbit anti-KIF5A (1:1000), Sigma-Aldrich; HPA004469 (**C**). Predicted molecular weight of KLC1 60-70kDa. Antibody used for detection was rabbit anti-KLC1 (1:5000), Abcam; Ab174273 (**D**). Predicted molecular weight of NeuN 48kDa. Antibody used for detection was rabbit anti-NeuN (1:5000), Abcam; Ab177487 (**E**). Predicted molecular weight of paired-helical filament tau 45-65kDa. Antibody used for detection was mouse anti-PHF-Tau (1:500), ThermoFisher Scientific; MN1020 (**F**). APP: amyloid precursor protein; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; kDa: kilodaltons; KIF: kinesin superfamily motor protein; KLC1: kinesin light chain-1; MW: molecular weight; PHF: paired helical filament; NeuN: neuronal nuclear protein.

to measure total A β in the fractions, with mouse monoclonal anti-A β (4G8 clone) (Biolegend; 800712; RRID: AB_2734548), for the capture step and biotinylated anti-human A β monoclonal antibody (10H3 clone) (ThermoFisher Scientific; MN1150B; RRID: AB_223641), for the detection step, as previously described³³.

Immunoperoxidase staining of paraffin sections

7 μ m sections from frontal cortex were dewaxed, hydrated, and immersed in 3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity. Sections were subsequently rinsed in running tap water and pre-treated with sodium citrate buffer in the microwave (0.01 M, pH 6.0, 5 min) to

unmask antigenic sites, then rinsed in PBS. Immunostaining was performed using VECTASTAIN® Universal Elite® ABC Kit (Vector Laboratories; PK-6200). Non-specific binding was blocked using horse serum for 30 min at room temperature, before incubation overnight at 4°C with anti-mouse monoclonal PHF-tau (1:2000) (ThermoFisher Scientific; MN1020; RRID: AB_223647), diluted in PBS. Sections were rinsed in PBS and incubated for 20 min with VECTASTAIN® biotinylated universal secondary antibody, followed by 20 min with VECTASTAIN® Elite® ABC complex (both Vector Laboratories; PK-6200), before a final 7 min with 3,3'-diaminobenzidine (DAB) (Vector Laboratories; SK4100). Sections were washed in water, immersed in copper sulphate DAB enhancer for 4 min (0.16 M Copper (II) sulphate 5-hydrate/0.12 M sodium chloride) and counterstained with Gills haematoxylin II (Sigma-Aldrich Ltd; GHS216) for 15 s. Sections were subsequently dehydrated, cleared and mounted in Clearium® (Leica Biosystems; 3801100). Controls in each run included sections incubated overnight in PBS instead of the primary antibody.

Immunohistochemical analysis

The percentage field fraction immunopositive for PHF-tau (insoluble tau load) was assessed in the cortex of frontal sections from AD and controls by computer-assisted image analysis using Histometrix software (Kinetic Imaging, Nottingham, UK) driving a Leica DM microscope with a motorised stage, as previously described^{34,35}. The area to be analysed was selected at low-magnification (x2.5) and the threshold for PHF-tau labelling density calibrated at high magnification (x20). The software was programmed to measure tau load in 30 random regions (x20 objective fields) within the selected area and determine the cumulative area fraction with a density exceeding the threshold value.

Statistical analysis

Univariate mRNA and protein analysis were performed using GraphPad Prism 5™ (GraphPad Software Inc.; San Diego,

USA). Data normality was tested using the Shapiro-Wilk test. One-way ANOVA with post-hoc Bonferroni, or Kruskal-Wallis with post-hoc Dunns test, as appropriate, was used to analyse differences in mRNA and protein expression according to Braak stages and SNP genotype. Parametric Pearson's or non-parametric Spearman's correlation was used to assess any relationship between proteins. A multiple regression model (STATA v12; StataCorp LLC; Texas, USA) was used to analyse mRNA expression in relation to Braak stage pathology, patient age of death and tissue post-mortem delay. Where necessary, data were transformed to normality before regression analysis. For all tests, values of $p < 0.05$ were considered statistically significant.

Results

Cohort variables

With exclusion criteria, the study cohort comprised 47 AD cases and 39 controls, as detailed in Table 1. The age of AD cases ranged from 54-98 y (mean 81, SD 9). Control cases ranged from 43-95 y (mean 80, SD 11). There were more females ($n = 29$) than males ($n = 18$) in the AD group, and fewer females ($n = 15$) than males ($n = 24$) in the controls. The PMD did not differ significantly between AD (37 h, SD 19) and controls (34 y, SD 20; two-tailed Mann-Whitney $p = 0.34$). There was no influence of PMD on *RBFOX3* (NeuN) mRNA (normalised to *GAPDH*; $n = 70$, Spearman $r = -0.09$, $p = 0.47$) or protein level (normalised to *GAPDH*; $n = 79$, Spearman $r = -0.02$, $p = 0.87$).

Significant increase in kinesin gene expression linked to AD pathology

Expression of kinesin relative to *RBFOX3* mRNA was measured by qPCR and analysed in relation to Braak tangle stage. *KIF5A* mRNA was significantly elevated at Braak stages III-IV ($p < 0.01$) and V-VI ($p < 0.001$), compared to stages I-II, (Figure 2A). *KLC1* mRNA was significantly elevated in late Braak stage disease (V-VI, $p < 0.001$) compared to stages I-II (Figure 2B). In

Figure 2. Upregulation of kinesin mRNA in Alzheimer's disease. Quantitative real-time PCR on cDNA from mid-frontal cortex of control and AD cases showed a significant increase in *KIF5A* mRNA in Braak stages III-IV ($n=11$) and V-VI ($n=35$) compared with Braak stages 0-II ($n=27$) (A). *KLC1* mRNA was significantly increased in Braak stages V-VI ($n=28$) but not stages III-IV ($n=12$), compared with Braak stages 0-II ($n=31$) (B). Results expressed as median, IQR and min/max quartile. Statistical test used: Kruskal-Wallis with post-hoc Dunns (A-B), ** $p < 0.01$, *** $p < 0.001$. AD: Alzheimer's disease, IQR: inter-quartile range, KIF: kinesin superfamily protein, *KLC1*: kinesin light chain-1, *RBFOX3*: RNA Binding Fox-1 Homolog 3.

a previous study we found an association between PMD and the level of *KIF5A* relative to *RBFOX3* (NeuN) mRNA²⁷ but in the present cohort we found no effect of either patient age at death or PMD on expression of *KIF5A* or *KLC1* relative to *RBFOX3* (Table 3).

Single nucleotide polymorphisms within the *KIF5A* gene locus influence *KIF5A* mRNA expression

We previously showed that *KIF5A* protein level was reduced in post-mortem brain tissue from MS patients homozygous for SNPs within the *KIF5A* gene locus which have been linked to MS susceptibility²⁶. We explored this in AD brain tissue using pre-designed TaqMan® SNP assays for *rs12368653* and *rs4646536*, the latter in linkage disequilibrium ($r^2 = 1$) with *rs703842*, making it suitable as a proxy^{36,37}. The accuracy of the SNP was verified using 18 MS positive control genotypes from our previous studies²⁶.

KIF5A mRNA expression was significantly lower in AD patients homozygous for the *rs12368653* SNP (AA) than in AD patients with no copies (GG) ($p < 0.05$; Figure 3A). Similarly, AD patients homozygous for the *rs4646536* SNP (AA) (proxy for *rs703842*), had significantly lower *KIF5A* mRNA than did heterozygous patients (AG) ($p < 0.05$; Figure 3B). There was no significant difference in *KLC1* mRNA expression in AD patients stratified according to *KIF5A* SNPs (*rs12368653* and *rs4646536*; Figure 3C and 3D). We subsequently investigated whether SNPs in the *KLC1* gene that were previously linked to AD susceptibility^{23,24} influence kinesin mRNA expression. There was no significant difference in *KLC1* mRNA between AD patients heterozygous for the *rs8702* SNP (GC) and those with no copies (GG; Figure 4A). Similarly, there was no significant difference in *KLC1* mRNA between AD patients heterozygous for the *rs8007903* SNP (AG) and those with no copies (AA; Figure 4B). Due to low cases numbers ($n=2$), homozygous expression could not be analysed. There was no significant effect of *KLC1* SNPs on *KIF5A* mRNA expression (Figure 4C and 4D).

Kinesin protein level does not vary significantly with AD pathology

Kinesin protein expression was measured by dot blot. In keeping with previous studies²⁷, *KIF5A* expression did not differ significantly between Braak stages 0-II, III-IV and V-VI (Figure 5A). In addition, there was no significant variation in *KLC1* protein level with Braak stage (Figure 5B). As expected, the levels of *KIF5A* and *KLC1* protein were positively correlated ($p < 0.001$, Figure 5C). There was no influence of SNPs within the *KIF5A* gene locus (*rs12368653* and *rs4646536*) on *KIF5A* (Figure 6A and 6B) or *KLC1* protein level (Figure 6C and 6D).

Kinesin levels inversely correlate with amyloid precursor protein in AD

As in previous studies^{27,38}, APP level did not differ significantly between AD and control cases (Figure 7A). APP levels correlated inversely with both *KIF5A* and *KLC1* protein in AD ($p < 0.05$; Figure 7B and 7C). Neither *KIF5A* or *KLC1* correlated with the level of soluble or insoluble A β or with the ratio of soluble: insoluble A β (Table 3), although a trend was seen for lower levels of soluble A β to be associated with higher levels of *KIF5A* ($p=0.10$; Table 3), as in our previous study²⁷. As expected, soluble and insoluble A β levels were significantly higher in AD than controls (Figure 8A and 8B).

KIF5A protein level correlates inversely with soluble paired helical filament tau

The level of hyperphosphorylated tau in the soluble protein fraction was significantly increased in AD compared with control cases (Figure 9A). The level correlated inversely with *KIF5A* protein level ($p < 0.05$) but not with *KLC1* protein in AD (Figure 9B and 9C). Western blot analysis showed additional bands above the predicted molecular weight of tau (45-65kDa), most likely attributed to phosphorylated epitopes³⁹. In addition to immunoblotting, hyperphosphorylated tau levels were measured by quantitative immunohistochemistry and showed a significant positive correlation with hyperphosphorylated tau protein

Table 3. Multiple regression analysis of cohort variables on kinesin mRNA expression.

Sample type	n	Variables	Coefficient	Standard error	t	p value	95% Confidence intervals	
<i>KIF5A</i> to <i>RBFOX3</i> mRNA	72	<i>Braak III-IV</i>	16.14	6.08	2.66	0.01	4.01	28.27
		<i>Braak V-VI</i>	31.12	3.90	7.98	0.00	23.33	38.91
		<i>Age at death</i>	0.08	0.20	0.40	0.69	-0.33	0.49
		<i>Post-mortem delay</i>	0.02	0.10	0.15	0.88	-0.19	0.22
<i>KLC1</i> to <i>RBFOX3</i> mRNA	70	<i>Braak III-IV</i>	-0.35	0.17	-2.04	0.05	-0.69	-0.01
		<i>Braak V-VI</i>	-0.77	0.12	-6.43	0.00	-1.01	-0.53
		<i>Age at death</i>	-0.00	0.01	-0.69	0.50	-0.02	0.01
		<i>Post-mortem delay</i>	-0.00	0.00	-0.09	0.93	-0.01	0.00

Significant correlations highlighted in red. Abbreviations: KIF: kinesin superfamily protein; *KLC1*: kinesin light chain-1; *RBFOX3*: RNA Binding Fox-1 Homolog 3.

Figure 3. Significant reduction in *KIF5A* mRNA expression in patients homozygous for SNPs within *KIF5A* gene locus. Homozygous AD carriers of *rs12368653* 'A' risk allele, (linked to MS susceptibility), had significantly lower levels of *KIF5A* mRNA (AA; n=6) than did non-carriers (GG; n=10) (**A**). Homozygous AD carriers of *rs703842* 'A' risk allele, (identified by proxy SNP *rs4646536*), also linked to MS susceptibility showed significant reduction in *KIF5A* mRNA (AA; n=18) compared to expression in heterozygous carriers (AG; n=17) (**B**). No significant difference in *KLC1* mRNA between homozygous (AA; n=6) or heterozygous (AG; n=22) AD carriers of *rs12368653* 'A' risk allele, (linked to MS susceptibility), compared to non-carriers (GG; n=8) (**C**). Homozygous (AA; n=17) or heterozygous (AG; n=14) AD carriers of *rs703842* 'A' risk allele, (identified by proxy SNP *rs4646536*), also linked to MS susceptibility, showed no significant difference in *KLC1* mRNA compared to non-carriers (GG; n=5) (**D**). Results expressed as median, IQR and min/max quartile. Statistical test used for **A** and **C**: one-way ANOVA, post-hoc Bonferroni Multiple Comparison. Statistical test used for **B** and **D**: Kruskal-Wallis test, post-hoc Dunn's Multiple Comparison; * p<0.05. AA: homozygous adenine, AD: Alzheimer's disease, AG: adenine/guanine, GG: homozygous guanine, IQR: inter-quartile range, KIF: kinesin superfamily protein, *KLC1*: kinesin light chain-1, MS: multiple sclerosis, *RBFOX3*: RNA Binding Fox-1 Homolog 3, SNP: single nucleotide polymorphism.

levels measured by dot blot (p<0.001; [Figure 9D](#)). There was no correlation between *KIF5A* or *KLC1* protein level and insoluble tau load ([Table 4](#)).

Discussion

Previous studies in mouse models implicated defective functioning of *KLC1* in disruption of axonal transport in AD^{21,40}. In the current study of human tissue from AD and control cases, we have found *KLC1* and *KIF5A* gene expression to be elevated in AD and associated with Braak tangle stage. We have also demonstrated significant inverse correlations between kinesin levels and AD-associated proteins, APP and PHF-tau. We did not find any association between *KLC1* gene expression and *KLC1* SNPs reportedly linked to AD.

Four *KLC* genes are expressed in mammals but those involved in axonal transport are *KLC1* and *KLC2*. *KLC1* is neuronally enriched whereas *KLC2* is ubiquitously expressed⁴¹. A coiled-coil region at the amino terminus of the *KLCs* binds to the stalk domain (close to the carboxyl terminus) of conventional kinesins (*KIF5A*, *KIF5B* and *KIF5C*) and acts as an adaptor complex for indirect binding and transport of cellular cargoes, such as APP²⁹.

Expression of both *KLC1* and *KIF5A* mRNA was positively associated with Braak tangle stage, a widely used marker of AD progression, defined by the distribution of hyperphosphorylated tau pathology distribution within the brain⁴². *KIF5A* mRNA was upregulated at relatively early stages of disease (Braak

Figure 4. No effect of SNPs within the *KLC1* gene on kinesin mRNA expression. No difference in *KLC1* mRNA between heterozygous carriers of *rs8702* 'C' risk allele linked to AD susceptibility (GC; n=14) and non-carriers (GG; n=21) (**A**). No difference in *KLC1* mRNA between heterozygous carriers of *rs8007903* 'G' risk allele linked to AD susceptibility (AG; n=7) and non-carriers (AA; n=26) (**B**). No difference in *KIF5A* mRNA between heterozygous carriers of *rs8702* 'C' risk allele linked to AD susceptibility (GC; n=17) and non-carriers (GG; n=24) (**C**). No difference in *KIF5A* mRNA between heterozygous carriers of *rs8007903* 'G' risk allele linked to AD susceptibility (AG; n=9) and non-carriers (AA; n=29) (**D**). Results expressed as median, IQR and min/max quartile. Statistical test used: two-tailed Mann-Whitney. AA: homozygous adenine, AD: Alzheimer's disease, AG: adenine/guanine, GC: guanine/cytosine, GG: homozygous guanine, IQR: inter-quartile range, KIF: kinesin superfamily protein, *KLC1*: kinesin light chain-1, MS: multiple sclerosis, *RBFOX3*: RNA Binding Fox-1 Homolog 3, SNP: single nucleotide polymorphism.

stages III-IV), in keeping with previously reported evidence of early-stage axonal abnormalities in AD and other neurodegenerative diseases^{13,21,40}. Upregulation of both *KIF5A* and *KLC1* mRNA may be a compensatory response to other pathological processes that interfere with axonal transport of protein cargoes to the synapse. Elevated kinesin gene expression in human tissue has been demonstrated in several neurodegenerative diseases^{15,28,43}.

Genome-wide association studies (GWAS) have shown linkage of multiple genes to AD susceptibility, including some genes encoding proteins with roles in axonal transport and cytoskeletal function (*NME8*, *CELF1*, and *CASS4*)³. However, GWAS are unable to detect rare variants linked to susceptibility. Such variants include SNPs within the *KLC1* gene, which have been linked to early AD pathogenesis. In particular, *rs8702* was reported to predict conversion from mild cognitive impairment to AD and was associated with levels of hyperphosphorylated tau in patient cerebrospinal fluid¹⁶. It is hypothesised that this SNP could

influence the splicing of c-terminal epitopes in *KLC1* gene transcripts¹⁶, which could affect cargo binding affinity, axonal transport and synaptic function, causing structural instability and eventual neuronal degeneration. The effective 'strain' on the neuron caused by transport defects is likely to be exacerbated by a reduction in mitochondrial ATP supply associated with aging⁴⁴. We found no effect on *KLC1* expression of heterozygosity of the *rs8702* 'C' risk allele or *rs8007903* 'G' allele but did not have sufficient cases to analyse the influence of homozygosity of the SNPs. Larger genetic studies found no effect of *rs8702* on AD susceptibility but a significant interaction with *APOE* $\epsilon 4$ carrier status in patients¹⁶. The continuing uncertainty as to the influence of *KLC1* polymorphisms on the risk of AD highlights the difficulties of linkage studies for rare variants, which are often hampered by small sample size, locus heterogeneity and false-positive results³.

We previously found a significant reduction in *KIF5A* expression in MS tissue in homozygous carriers of the *rs703842* 'A'

Figure 5. No change in conventional kinesin expression in Alzheimer's disease. No significant difference in KIF5A between Braak stages 0-II (n=29), III-IV (n=12) and V-VI (n=34), on dot blot analysis of protein extracted from homogenised control and AD mid-frontal cortex (A). No difference in KLC1 protein between Braak stages 0-II (n=28), III-IV (n=11) and V-VI (n=35) (B). Protein levels of KIF5A correlated positively with that of KLC1 (n=86; C). Results expressed as median, IQR and min/max quartile. Statistical test used: Kruskal-Wallis test, post-hoc Dunn's Multiple Comparison (A–B). Spearman correlation represented as line of best fit +/- 95% CI (C); *** $p < 0.001$. AD: Alzheimer's disease, CI: confidence intervals, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, NeuN: neuronal nuclear protein.

allele and *rs12368653* 'A' allele^{25,26}, which are linked to MS susceptibility^{36,45}. GWAS have identified susceptibility variants common to MS and sporadic AD, including major histocompatibility complex gene *HLA-DRB1*³. In the present study, we found a significant reduction in *KIF5A* mRNA expression in AD patients homozygous for the *rs4646536* 'A' allele (proxy for *rs703842*³⁷) and *rs12368653* 'A' allele, compared to heterozygotes and non-carriers. Variability within the *KIF5A* gene locus may be a common denominator across a spectrum of neurodegenerative conditions. *KIF5A* mutations are linked to several axonopathies, including hereditary spastic paraplegia and Charcot-Marie Tooth Disease^{46,47}. More recently, a mutation in the cargo binding domain of *KIF5A* was shown to be associated with amyotrophic lateral sclerosis (ALS)⁴⁸.

Unlike our findings in MS, although the *KIF5A* genotype influenced mRNA expression in AD it did not have a detectable effect on expression of the protein. We previously found increased

KIF5A protein in AD, although no significant association with Braak stage²⁷. Similarly, in the present study we found no significant association between *KIF5A* or *KLC1* and Braak stage. It is possible that reduced protein clearance, a common finding in age-related neurodegenerative diseases⁴⁹, could partly compensate for reduced *KIF5A* synthesis in the later stages of AD. $A\beta$ itself may influence kinesin metabolism and recent *in vitro* and *in vivo* studies using a FAD mouse model have shown $A\beta$ reduces *KIF5A* expression and disrupts *KIF5A*-mediated mitochondrial transport⁵⁰. Previous studies found reduced *KLC1* protein in AD frontal cortex⁵¹ and reduced *KLC1* expression in the presence of soluble $A\beta$ trimers⁵². Assay sensitivity may also be relevant and some changes in *KLC1* metabolism missed due to the complex carboxyterminal splicing, which results in multiple variants⁵³ with varied affinities for the antibody used in the present study. Evidence from one study suggests that alternative splicing of *KLC-1* can create a functional variant (E) that causes $A\beta$ accumulation⁵⁴. Co-immunoprecipitation studies

Figure 6. Kinesin protein expression in AD patients homozygous for SNPs within the *KIF5A* gene locus. No difference in KIF5A protein between homozygous AD carriers of *rs12368653* 'A' risk allele, linked to MS susceptibility, (AA; n=9) and heterozygotes (AG; n=21) or non-carriers (GG; n=6) (**A**). No difference in KIF5A protein between homozygous AD carriers of *rs703842* 'A' risk allele, (identified by proxy SNP *rs4646536*) linked to MS susceptibility, (AA; 15) and heterozygotes (AG; n=17) or non-carriers (GG; n=4) (**B**). No difference in KLC1 protein between homozygous AD carriers of *rs12368653* 'A' risk allele, linked to MS susceptibility, (AA; n=6) and heterozygotes (AG; n=21) or non-carriers (GG; n=10) (**C**). No difference in KLC1 protein between homozygous AD carriers of *rs703842* 'A' risk allele, (identified by proxy SNP *rs4646536*) linked to MS susceptibility, (AA; 17) and heterozygotes (AG; n=17) or non-carriers (GG; n=5) (**D**). Results expressed as median, IQR and min/max quartile. Statistical test used: one-way ANOVA, post-hoc Bonferroni Multiple Comparison. AA: homozygous adenine, AD: Alzheimer's disease, AG: adenine/guanine, GG: homozygous guanine, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, MS: multiple sclerosis, NeuN: neuronal nuclear protein.

have demonstrated at least 6 variants of conventional kinesin (KIF- 5A/5B/5C with KLC1 or KLC2); however, with alternative splicing of KLC1 the number is likely to be much higher³⁰. The multiplicity of splice variants is attributed to the large variety of membrane cargoes that require transportation to distinct neuronal compartments¹. For future studies, it would be interesting to study the expression pattern of additional KIF5 (5B and 5C) and KLC (KLC-2) family members, for expression profiling in different cortical regions of AD brain.

Irrespective of overall kinesin protein levels, evidence points to disruption of convention kinesin transport in AD, through phosphorylation-mediated dissociation of KIF from both its cargo and from the microtubule³⁵. Studies of transgenic mouse models have suggested that A β can be transported within neurites and have shown a correlation between axonal swellings positive for intracellular A β and the location of extracellular insoluble A β deposits²². In addition, studies in the squid giant

axon have shown that A β oligomers can inhibit axonal transport through activation of casein kinase 2, which phosphorylates KLC1, reducing its cargo binding affinity^{56,57}. We found no significant correlation between KIF5A or KLC1 and insoluble A β levels, despite a trend towards lower soluble A β with higher KIF5A, as in our previous study²⁷. We found significant inverse correlations between APP expression and both KIF5A and KLC-1. From this, we hypothesise that reduced APP transport by kinesin prolongs exposure of APP to secretases and increases amyloidogenic cleavage, which creates a negative feedback loop for A β -mediated impaired axonal transport⁵⁸, although further experiments are required to validate this hypothesis.

There was a significant negative correlation between KIF5A and soluble hyperphosphorylated tau levels, but not with the insoluble tau load as determined immunohistochemically. Pathogenic forms of tau enhance glycogen synthase kinase 3 β (GSK3 β)

Figure 7. Kinesin levels correlate inversely with APP expression in AD. No significant difference in APP between control (n=36) and AD cases (n=40) on dot blot analysis of protein extracted from homogenised control and AD mid-frontal cortex (**A**). Significant inverse correlation between KIF5A (normalised to GAPDH) and APP (normalised to NeuN) protein levels in AD (n=38; **B**). KLC1 level (normalised to GAPDH) correlated inversely with APP level (normalised to NeuN) in AD cases (n=37; **C**). Results expressed as median, IQR and min/max quartile. Statistical test used two-tailed t-test (**A**). Pearson correlations represented as line of best fit +/- 95% CI (**B–C**); * $p < 0.05$. AD: Alzheimer's disease, APP: amyloid precursor protein, CI: confidence intervals, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, NeuN: neuronal nuclear protein.

Figure 8. Expression of A β in mid-frontal cortex. Soluble A β significantly increased in AD cases (n=40) compared with control (n=18) from ELISA analysis (**A**). Insoluble A β significantly higher in AD cases (n=41) compared to control (n=23; **B**). Results expressed as median, IQR and min/max quartile. Statistical test used: two-tailed Mann-Whitney; ** $p < 0.01$. A β : amyloid beta, AD: Alzheimer's disease, IQR: inter-quartile range.

Figure 9. KIF5A levels correlate inversely with hyperphosphorylated tau expression in Alzheimer's disease. Significant increase in PHF-tau in AD cases (n=44) compared with control (n=35; **A**). Significant inverse correlation between KIF5A (normalised to GAPDH) and PHF-Tau (normalised to NeuN) in AD (n=44; **B**). No significant correlation between KLC1 levels (normalised to GAPDH) and PHF-Tau protein (normalised to NeuN) in AD (n=44; **C**). The level of soluble PHF-Tau (as measured by dot blot) showed a significant positive correlation with insoluble hyperphosphorylated tau load (as determined by IHC) in AD cases (n=44; **D**). Results expressed as median, IQR and min/max quartile. Statistical test used two-tailed Mann-Whitney (**A**). Spearman correlations represented as line of best fit $\pm$ 95% CI (**B-D**); * $p < 0.05$, *** $p < 0.001$. AD: Alzheimer's disease, CI: confidence intervals, GAPDH: glyceraldehyde 3-phosphate dehydrogenase, IHC: immunohistochemistry, IQR: inter-quartile range, KIF: kinesin superfamily protein, KLC1: kinesin light chain-1, NeuN: neuronal nuclear protein, PHF: paired helical filament.

activity by increasing exposure of the phosphatase-activating domain in the amino terminus of tau, which increases protein-phosphatase 1-dependent activation of GSK3 β ⁵⁹. Elevated GSK3 β causes KLC1 phosphorylation and results in protein cargo dissociation⁴⁰.

Kinesin phosphorylation is emerging as a potent modulator of axonal transport in neurodegenerative diseases and this pathway presents a potential modifiable target for treatment^{1,60}. Based on the previous phosphorylation studies mentioned and our human tissue findings, it seems that the relationship between kinesin protein expression and AD pathology would be better untangled using a transgenic mouse model of AD. Recent studies have highlighted the advantages of using *in vivo* time-lapse imaging in a rodent model for monitoring changes in axonal transport⁶¹. Studies in ALS mouse models using *in vivo* time-lapse have indicated axonal transport disturbances represent an early

change in disease pathology and are not merely a 'by-product' of insidious neurodegeneration⁶². This *in vivo* imaging technology could be employed to explore early changes in the frequency and speed of KIF5A/KLC-1 mediated vesicle transport in familial (APP/presenilin 1 mutation) AD mouse models. The technology would also allow for a more in-depth analysis of any potential transport redundancy between KIF5A and KLC-1 using gene silencing or interference. In addition, *in vivo* imaging could be used to explore the role of phosphorylation-mediated kinesin cargo uncoupling which has been highlighted in other AD mouse studies and would allow for testing of various kinase inhibitors on restoring axonal transport rates.

Overall, we show that both KIF5A and KLC-1 mRNA are upregulated in AD tissue and that genetic polymorphisms within the KIF5A gene locus influence KIF5A gene expression. The findings do not indicate that upregulation of KIF5A is a result

Table 4. Univariate correlation of kinesin and proteins associated with neuronal pathology.

Motor protein	Cargo protein	Sample	n	Correlation coefficient (r)	Significance (p)
KIF5A	APP	Control	33	-0.27	0.13
		AD	38	-0.41	0.01
	PHF-tau	Control	35	-0.17	0.35
		AD	44	-0.36	0.02
	Tau load	AD	42	0.10	0.52
	Insoluble A β	Control	22	0.25	0.25
		AD	37	-0.13	0.46
	Soluble A β	Control	19	0.14	0.58
		AD	37	-0.28	0.10
	Soluble: Insoluble A β	Control	14	-0.06	0.84
		AD	32	0.02	0.90
KLC1	APP	Control	34	-0.28	0.11
		AD	37	-0.34	0.04
	PHF-Tau	Control	33	-0.28	0.11
		AD	37	-0.24	0.14
	Tau load	AD	43	-0.05	0.73
	Insoluble A β	Control	22	0.29	0.20
		AD	39	0.03	0.88
	Soluble A β	Control	19	0.15	0.35
		AD	33	0.02	0.93
	Soluble: Insoluble A β	Control	14	-0.15	0.62
		AD	33	0.12	0.52

Significant correlations highlighted in red. Abbreviations: A β : amyloid beta; APP: amyloid precursor protein; KIF: kinesin superfamily protein; KLC1: kinesin light chain-1; PHF: paired helical filament.

of functional redundancy between KIF5A and KLC1 in protein transport, or that the expression of KLC1 in cerebral cortex is influenced by *KLC1* polymorphisms, which have been linked to AD susceptibility. In future studies it would be useful to perform full expression profiling of KIF5 and KLC members in post-mortem tissue from multiple cortical regions. In addition, further studies analysing the effect of kinesin upregulation (and highlighted KIF genetic polymorphisms), on axonal transport mechanisms, through both *in vitro* axonal cultures and *in vivo* AD rodent models, using time-lapse imaging would be of significant interest.

Data availability

The raw data files used for figure generation are available at the University of Bristol data repository, data.bris

Data.bris: Dataset 1. Data from BRACE pilot: axonal proteins (01-2019), <https://doi.org/10.5523/bris.23clppyx8fj92uf97zr2u41vc>⁶³

Licence: [Non-Commercial Government License for public sector information](#)

Immunohistochemical counts of insoluble tau load on AD cases were provided by the South West Dementia Brain Bank (SWDBB), as part of their archived data on Brain Bank cases. Due to the historic nature of the data set, the original IHC images are no longer available.

Grant information

This work was supported by a pilot grant from BRACE (Bristol Research into Alzheimer's and Care of the Elderly).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We thank the South West Dementia Brain Bank (SWDBB) for providing brain tissue for this study. The SWDBB is part of the Brains for Dementia Research program, jointly funded by Alzheimer's Research UK and the Alzheimer's Society, and is supported by BRACE and the Medical Research Council.

References

1. Brady ST, Morfini GA: **Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases.** *Neurobiol Dis.* 2017; **105**: 273–282.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Bu G: **Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy.** *Nat Rev Neurosci.* 2009; **10**(5): 333–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Giri M, Zhang M, Lü Y: **Genes associated with Alzheimer's disease: an overview and current status.** *Clin Interv Aging.* 2016; **11**: 665–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Brady S, Morfini G: **A perspective on neuronal cell death signaling and neurodegeneration.** *Mol Neurobiol.* 2010; **42**(1): 25–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Coleman M: **Molecular signaling how do axons die?** *Adv Genet.* 2011; **73**: 185–217.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Cheng HC, Ulane CM, Burke RE: **Clinical progression in Parkinson disease and the neurobiology of axons.** *Ann Neurol.* 2010; **67**(6): 715–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Lingor P, Koch JC, Tönges L, et al.: **Axonal degeneration as a therapeutic target in the CNS.** *Cell Tissue Res.* 2012; **349**(1): 289–311.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Stokin GB, Lillo C, Falzone TL, et al.: **Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.** *Science.* 2005; **307**(5713): 1282–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Hirokawa N, Noda Y: **Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics.** *Physiol Rev.* 2008; **88**(3): 1089–118.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Brady ST: **A novel brain ATPase with properties expected for the fast axonal transport motor.** *Nature.* 1985; **317**(6032): 73–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Miki H, Setou M, Kaneshiro K, et al.: **All kinesin superfamily protein, KIF, genes in mouse and human.** *Proc Natl Acad Sci U S A.* 2001; **98**(13): 7004–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Hirokawa N, Niwa S, Tanaka Y: **Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease.** *Neuron.* 2010; **68**(4): 610–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Morfini GA, Burns M, Binder LI, et al.: **Axonal transport defects in neurodegenerative diseases.** *J Neurosci.* 2009; **29**(41): 12776–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Roy S, Zhang B, Lee VM, et al.: **Axonal transport defects: a common theme in neurodegenerative diseases.** *Acta Neuropathol.* 2005; **109**(1): 5–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Kreft KL, van Meurs M, Wierenga-Wolf AF, et al.: **Abundant kif21b is associated with accelerated progression in neurodegenerative diseases.** *Acta Neuropathol Commun.* 2014; **2**(1): 144.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Andersson ME, Sjölander A, Andreassen N, et al.: **Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease.** *Int J Mol Med.* 2007; **20**(2): 233–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Kamal A, Almenar-Queralt A, LeBlanc JF, et al.: **Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP.** *Nature.* 2001; **414**(6864): 643–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Kamal A, Stokin GB, Yang Z, et al.: **Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I.** *Neuron.* 2000; **28**(2): 449–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Lazarov O, Morfini GA, Lee EB, et al.: **Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited.** *J Neurosci.* 2005; **25**(9): 2386–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Szodrai A, Kuan YH, Hunzelmann S, et al.: **APP anterograde transport requires Rab3A GTPase activity for assembly of the transport vesicle.** *J Neurosci.* 2009; **29**(46): 14534–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Falzone TL, Stokin GB, Lillo C, et al.: **Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects.** *J Neurosci.* 2009; **29**(18): 5758–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Christensen DZ, Huettenrauch M, Mitkovski M, et al.: **Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal A β accumulation.** *Front Aging Neurosci.* 2014; **6**: 139.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Dhaenens CM, Van Brussel E, Schraen-Maschke S, et al.: **Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease.** *Neurosci Lett.* 2004; **368**(3): 290–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. von Otter M, Landgren S, Nilsson S, et al.: **Kinesin light chain 1 gene haplotypes in three conformational diseases.** *Neuromolecular Med.* 2010; **12**(3): 229–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Hares K, Kemp K, Rice C, et al.: **Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis.** *Mult Scler.* 2014; **20**(7): 812–821.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Hares K, Redondo J, Kemp K, et al.: **Axonal motor protein KIF5A and associated cargo deficits in multiple sclerosis lesional and normal-appearing white matter.** *Neuropathol Appl Neurobiol.* 2017; **43**(3): 227–241.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Hares K, Miners JS, Cook AJ, et al.: **Overexpression of Kinesin Superfamily Motor Proteins in Alzheimer's Disease.** *J Alzheimers Dis.* 2017; **60**(4): 1511–1524.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Stamper C, Siegel A, Liang WS, et al.: **Neuronal gene expression correlates of Parkinson's disease with dementia.** *Mov Disord.* 2008; **23**(11): 1588–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Morfini G, Schmidt N, Weissmann C, et al.: **Conventional kinesin: Biochemical heterogeneity and functional implications in health and disease.** *Brain Res Bull.* 2016; **126**(Pt 3): 347–353.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. DeBoer SR, You Y, Szodrai A, et al.: **Conventional kinesin holoenzymes are composed of heavy and light chain homodimers.** *Biochemistry.* 2008; **47**(15): 4535–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Montine TJ, Phelps CH, Beach TG, et al.: **National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.** *Acta Neuropathol.* 2012; **123**(1): 1–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Glennon EB, Whitehouse LJ, Miners JS, et al.: **BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging.** *PLoS One.* 2013; **8**(10): e78806.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. van Helmond Z, Miners JS, Kehoe PG, et al.: **Oligomeric A β in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy.** *Brain Pathol.* 2010; **20**(2): 468–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Chalmers KA, Wilcock GK, Vinters HV, et al.: **Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.** *J Neurol.* 2009; **256**(5): 717–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Ballard CG, Chalmers KA, Todd C, et al.: **Cholinesterase inhibitors reduce cortical A β in dementia with Lewy bodies.** *Neurology.* 2007; **68**(20): 1726–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Alcina A, Fedetz M, Fernández O, et al.: **Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis.** *J Med Genet.* 2013; **50**(1): 25–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene): **Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20.** *Nat Genet.* 2009; **41**(7): 824–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Holtzman DM, Mobley WC: **Molecular studies in Alzheimer's disease.** *Trends Biochem Sci.* 1991; **16**(4): 140–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Buée L, Bussire T, Bue-Scherrer V, et al.: **Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.** *Brain Res Brain Res Rev.* 2000; **33**(1): 95–130.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Pigino G, Morfini G, Pelsman A, et al.: **Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport.** *J Neurosci.* 2003; **23**(11): 4499–508.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Cockburn JJB, Hesketh SJ, Mulhair P, et al.: **Insights into Kinesin-1 Activation from the Crystal Structure of KLC2 Bound to JIP3.** *Structure.* 2018; **26**(11): 1486–1498 e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Braak H, Braak E: **Staging of Alzheimer's disease-related neurofibrillary changes.** *Neurobiol Aging.* 1995; **16**(3): 271–8; discussion 278–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Kuzma-Kozakiewicz M, Kamierczak B, Chudy A, et al.: **Alteration of Motor Protein Expression Involved in Bidirectional Transport in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis.** *Neurodegener Dis.* 2016; **16**(3–4): 235–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Federico A, Cardaioli E, Da Pozzo P, et al.: **Mitochondria, oxidative stress and neurodegeneration.** *J Neurol Sci.* 2012; **322**(1–2): 254–62.
[PubMed Abstract](#) | [Publisher Full Text](#)

45. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium, Sawcer S, *et al.*: **Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.** *Nature*. 2011; **476**(7359): 214–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Crimella C, Baschiroto C, Arnoldi A, *et al.*: **Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot-Marie-Tooth type 2.** *Clin Genet*. 2012; **82**(2): 157–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Reid E, Kloos M, Ashley-Koch A, *et al.*: **A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10).** *Am J Hum Genet*. 2002; **71**(5): 1189–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Brenner D, Yilmaz R, Müller K, *et al.*: **Hot-spot KIF5A mutations cause familial ALS.** *Brain*. 2018; **141**(3): 688–697.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Vilchez D, Saez I, Dillin A: **The role of protein clearance mechanisms in organismal ageing and age-related diseases.** *Nat Commun*. 2014; **5**: 5659.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Wang Q, Tian J, Chen H, *et al.*: **Amyloid beta-mediated KIF5A deficiency disrupts anterograde axonal mitochondrial movement.** *Neurobiol Dis*. 2019; **127**: 410–418.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Morel M, Héraud C, Nicaise C, *et al.*: **Levels of kinesin light chain and dynein intermediate chain are reduced in the frontal cortex in Alzheimer's disease: Implications for axoplasmic transport.** *Acta Neuropathol*. 2012; **123**(1): 71–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Sherman MA, LaCroix M, Amar F, *et al.*: **Soluble Conformers of A β and Tau Alter Selective Proteins Governing Axonal Transport.** *J Neurosci*. 2016; **36**(37): 9647–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Cyr JL, Pfister KK, Bloom GS, *et al.*: **Molecular genetics of kinesin light chains: generation of isoforms by alternative splicing.** *Proc Natl Acad Sci U S A*. 1991; **88**(22): 10114–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Morihara T, Hayashi N, Yokokoji M, *et al.*: **Transcriptome analysis of distinct mouse strains reveals kinesin light chain-1 splicing as an amyloid- β accumulation modifier.** *Proc Natl Acad Sci U S A*. 2014; **111**(7): 2638–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Kanaan NM, Pigino GF, Brady ST, *et al.*: **Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.** *Exp Neurol*. 2013; **246**: 44–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Moreno H, Yu E, Pigino G, *et al.*: **Synaptic transmission block by presynaptic injection of oligomeric amyloid beta.** *Proc Natl Acad Sci U S A*. 2009; **106**(14): 5901–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Pigino G, Morfini G, Atagi Y, *et al.*: **Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta.** *Proc Natl Acad Sci U S A*. 2009; **106**(14): 5907–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Gan KJ, Morihara T, Silverman MA: **Atlas stumbled: kinesin light chain-1 variant E triggers a vicious cycle of axonal transport disruption and amyloid- β generation in Alzheimer's disease.** *Bioessays*. 2015; **37**(2): 131–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. LaPointe NE, Morfini G, Pigino G, *et al.*: **The amino terminus of tau inhibits kinesin-dependent axonal transport: Implications for filament toxicity.** *J Neurosci Res*. 2009; **87**(2): 440–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Gibbs KL, Greensmith L, Schiavo G: **Regulation of Axonal Transport by Protein Kinases.** *Trends Biochem Sci*. 2015; **40**(10): 597–610.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Gibbs KL, Kalmar B, Sleight JN, *et al.*: **In vivo imaging of axonal transport in murine motor and sensory neurons.** *J Neurosci Methods*. 2016; **257**: 26–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Sleight JN, Tosolini AP, Gordon D, *et al.*: **ALS mice carrying pathological mutant TDP-43, but not mutant FUS, display axonal transport defects in vivo.** *bioRxiv*. 2018.
[Publisher Full Text](#)
63. Hares K, Wilkins A: **Data from BRACE pilot: axonal proteins (01-2019).** 2019.
<http://www.doi.org/10.5523/bris.23clppyyx8fj92uf97zr2u41vc>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 01 August 2019

<https://doi.org/10.21956/amrcopenres.13946.r26443>

© 2019 Gustavo G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gustavo F. Gustavo

Instituto de Investigación Médica Mercedes y Martín Ferreyra, INIMEC-CONICET-Universidad Nacional de Córdoba, Córdoba, Argentina

Dr. Hares and co-workers have modified the previous version of the manuscript, included new information and wrote the manuscript less speculative, as well as clarified the proposed hypothesis. The new version has acknowledged the previous limitations and proposed new experiments to be able to extend their previous conclusions.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: I work on axonal transport and neurodegeneration

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 11 April 2019

<https://doi.org/10.21956/amrcopenres.13927.r26330>

© 2019 Gray E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Elizabeth Gray

Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford,

Oxford, UK

Hares et al. describe the expression of KLC1 and KIF5A gene and protein expression in the mid frontal cortex of Alzheimers Disease compared to healthy control patients. This study builds upon their body of work and observations of the kinesin expression in Multiple Sclerosis. The methodological approaches used are appropriate to address the questions being asked in the study and I would recommend this manuscript for indexing with the following addition to the discussion of the manuscript. Could the authors comment and perhaps discuss the relevance and potential merits of the use of live imaging of axonal transport in animal models of AD and how they may attempt to relate this to KIF5A and KLC protein expression in these models. Please see relevant references below.

References

1. Gibbs KL, Kalmar B, Sleight JN, Greensmith L, et al.: In vivo imaging of axonal transport in murine motor and sensory neurons. *J Neurosci Methods*. 2016; **257**: 26-33 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Sleight J, Tosolini A, Gordon D, Devoy A, et al.: ALS mice carrying pathological mutant TDP-43, but not mutant FUS, display axonal transport defects in vivo. *bioRxiv*. 2018. [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neurodegeneration, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Neuropathology, Neurofilaments, Biomarkers.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 17 Jun 2019

Kelly Hares, University of Bristol, Bristol, UK

We thank the reviewer for their comments and insight. We have expanded the discussion to include the merits of studying axonal transport in AD rodent models and have included the relevant references (page 16).

Competing Interests: No competing interests were disclosed.

Reviewer Report 02 April 2019

<https://doi.org/10.21956/amrcopenres.13927.r26328>

© 2019 Brady S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Scott T. Brady

Department of Anatomy and Cell Biology, University of Illinois at Chicago (UIC), Chicago, IL, USA

A substantial literature has implicated axonal transport deficits as a component of pathogenesis in AD and other adult-onset neurodegenerative diseases. Some evidence has been published from GWAS studies suggesting that altered expression of molecular motor proteins or genetic polymorphisms in KLC1 may be risk factors for AD, but relatively little has been done to document specific changes in patient materials. In this study, the investigators have evaluated expression of two genes that are candidates for a role in AD, taking advantage of access to midfrontal cortex tissue from 47 AD and 39 control human brains. The set of brains are relatively well matched in terms of mean age and postmortem delay for control and AD. Based on age at the time of death, the AD patients are likely to be mostly sporadic cases with 5-10% familial cases, which is consistent with the population levels. Both males and females are considered together. The authors do not stratify by familial vs sporadic or male vs female.

The focus here is on expression of KIF5A and KLC1, both of which have been reported to have polymorphisms associated with neurological diseases. In addition, the authors cite literature claiming that KIF5A complexed to KLC1 is responsible for transport of vesicles containing APP as well as b- and g-secretases. Unfortunately, those studies have never been replicated despite concerted effort by multiple groups (see for example O. Lazarov, *et al.* (2007). *Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1*¹). A more rigorous study of APP transport showed that the primary motor was KIF5C and that neither b- or g-secretases were co-transported (A. Szodorai, *et al.* (2009). *APP anterograde transport requires Rab3A GTPase activity for assembly of the transport vesicle*²). Nevertheless, evidence from this group and others that show increased expression of KIF5A in AD and data from GWAS and transcriptomic studies showing association of polymorphisms and splice variants of KLC1 with AD justify analysis of expression for these two genes.

The data showed an increase in mRNA for KIF5A confirming previous studies and indicate that

KLC1 mRNA levels also increase. Data is also presented on changes in expression related to a polymorphism in KIF5A previously associated with reduced KIF5A and susceptibility to multiple sclerosis. While a small difference was seen with the AA genotype that was significant when analyzed by ANOVA, the effects were modest at best and were not compelling. No differences were detected with polymorphisms in KLC1. Similarly, protein levels of KIF5A and KLC1 were not different with either polymorphisms or Braak stage. The authors then looked at levels of Aband PHF-tau, finding that, of course, they both increase in the AD patients. Not surprisingly, the KIF5A levels correlated inversely with increased which is to be expected since KIF5A levels don't change while the Aband PHF-tau increase. Given the scatter of the data, it is not clear that these are meaningful correlations.

In sum, this is a modest advance on previously published observations that largely yielded negative results. This may in part be due to the limited number of targets being investigated and questions as to whether they represent the right targets to evaluate. There are challenges associated with analyzing post-mortem human brains that inevitably exhibit substantial variants even in the most carefully executed studies. Unfortunately, even when sophisticated statistical tests are employed, the physiological relevance can be difficult to determine. This is particularly true when the absolute differences are small. This can be mitigated in part by using plots that show the actual data points (as in figures 5, 7 and 8), but the conclusions that can be drawn from this dataset are limited. Certainly, they do not provide much support for the overall conclusions. A more comprehensive study looking at changes at the full range of KIF5 and KLC forms would help as would comparisons to brain regions that are not associated with AD pathology (i.e. cerebellum and sensory cortex for example). However, in its present form, the impact of this study is limited.

References

1. Lazarov O, Morfini GA, Pigino G, Gadadhar A, et al.: Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. *J Neurosci.* 2007; **27** (26): 7011-20 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Szodorai A, Kuan YH, Hunzelmann S, Engel U, et al.: APP anterograde transport requires Rab3A GTPase activity for assembly of the transport vesicle. *J Neurosci.* 2009; **29** (46): 14534-44 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: cell and molecular neuroscience, axonal transport, and adult onset neurodegeneration.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 17 Jun 2019

Kelly Hares, University of Bristol, Bristol, UK

We thank the reviewer for their comments. We have amended the conclusion to better reflect the study findings (Page 17). We appreciate that the literature surrounding the transport of APP is divided and we have added the references cited by the reviewer to the introduction (Page 4). Nevertheless, recent evidence from *in vitro* and AD mouse models suggest KLC-1 splice variants act as an A β modifier (Moriyama, et al. 2014). It is hypothesised this effect could be mediated through reduced APP transport and reduced transport of other cargoes linked to APP proteolysis (ApoER2, calyculin and JLP) (Gan, et al. 2014).

We feel our protein correlation analysis is meaningful but accept correlation analyses need to be interpreted in the wider context. We did see a significant increase in A β and PHF-Tau expression in AD but to clarify the reviewer's comments, the significant correlations we have reported are between APP and KIF5A/KLC and we did not detect a significant increase in APP in AD. In addition, the correlation with PHF-tau was only significant with KIF5A but not KLC-1.

Although the results were largely negative in terms of our initial hypotheses, we do feel the data itself is robust and the results are of interest to others. We did see significant changes in KIF5A and KLC-1 gene expression and a rise in KIF5A gene expression at early Braak stages (III-IV). We also saw genotype influenced KIF5A gene expression in AD patients homozygous for a SNP within the KIF5A gene locus that has previously been linked to MS susceptibility. We agree that at present, the results appear modest, however the data analysed by One-Way ANOVA was significant and given our findings in MS tissue, we felt it was important to present this preliminary discovery and that it warrants future investigation. The data presented in this manuscript are the result of a pilot-funded study. We agree, in the context of a larger study, it would be interesting to analyse multiple KIF5 and KLC isoforms and this point has been added to the discussion, alongside other possibilities for expanding this work (Page 15-19).

Competing Interests: No competing interests were disclosed.

Reviewer Report 15 March 2019

<https://doi.org/10.21956/amrcopenres.13927.r26309>

© 2019 Gustavo G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gustavo F. Gustavo

Instituto de Investigación Médica Mercedes y Martín Ferreyra, INIMEC-CONICET-Universidad Nacional de Córdoba, Córdoba, Argentina

In the present manuscript Kelly Hares and co-workers aimed (as stated by the authors) “to determine whether KLC1 levels are altered in AD, the relationship between the levels of KLC1 and KIF5A, and whether expression of KLC1 in the cerebral cortex is influenced by KLC1 polymorphisms, which have been linked to AD susceptibility.”

The authors determined the kinesin mRNA levels relative to RBFOX3 by qPCR, in relation to Braak tangle stage, in a cohort composed of 47 AD cases and 39 controls without any significant PMD alteration between analyzed samples.

The authors found:

- KIF5A mRNA levels were significantly elevated at Braak stages III-IV and V-VI in comparison with stages I-II
- KLC1 mRNA levels were significantly elevated in late Braak stages V-VI compared to stages I-II

With respect to protein levels the authors found:

- In contrast to previous discoveries by the same group, the authors found that KIF5A protein levels did not change between Braak stages 0-II, III-IV or V-VI. It is worth mentioning that the present results were obtained working with a different cohort of control and AD brain samples than in the previous manuscripts (Hares K et al., 2017¹)
- The authors did not observe significant variations in KLC1 protein levels with Braak stages.
- No influence of SNPs within the KIF5A gene locus (rs12368653 and rs4646536) on KIF5A or KLC1 protein levels.

Correlation between Kinesin levels and amyloid precursor protein:

- As reported before, authors found that APP protein level did not differ between AD and control cases.
- The authors found that APP protein levels correlated inversely with KIF5A and KLC1 in AD
- The authors found that neither KIF5A or KLC1 correlated with the level of soluble or insoluble A β . The authors observed a trend, although not statistically significant, for lower levels of soluble A β to be associated with higher levels of KIF5A.
- The authors found that soluble and insoluble A β were significantly higher in AD than controls, corroborating previous reports from other groups.

Correlation between KIF5A levels and hyperphosphorylated tau:

- The levels of hyperphosphorylated tau in the soluble protein fraction was increased in AD compared with control cases, corroborating previous data from other groups.
- The levels of hyperphosphorylated tau correlated inversely with KIF5A protein level but not with KLC1 protein level in AD.
- No correlation between KIF5A or KLC1 protein levels and insoluble tau load.

With respect to SNPs in KIF5A locus linked to MS susceptibility in AD patients the authors found:

- KIF5A mRNA levels were significantly lower in AD patients homozygous for the KIF5A gene locus linked to MA susceptibility rs12368653 SNP (AA) than in AD patients with no copies (GG).
- Similarly, KIF5A mRNA expression was significantly lower in AD patients homozygous for the gene locus linked to MA susceptibility rs4646536 SNP (AA) than did heterozygous AD patients (AG).
- KLC1 mRNA expression was not significantly different in AD patients stratified according to KIF5A SNPs either rs12368653 or rs4646536

With respect to SNPs in KLC1 locus linked to AD susceptibility in AD patients the authors found:

- No significant difference in KLC1 mRNA expression between AD patients heterozygous for the rs8702 SNP (GC) and those with no copies (GG).
- No significant difference in KLC1 mRNA expression between AD patients heterozygous for the rs8007903 SNP (AG) and those with no copies (AA).
- No significant effects of KLC1 SNPs on KIF5A mRNA expression.

Discussion Section:

The authors discuss that they found KLC1 and KIF5A mRNA levels to be elevated in AD associated with Braak tangle stages. Hares and coworkers found an inverse correlation between kinesin levels and AD-associated proteins. It is worth mentioning that the inverse correlation is observed only with APP but not with soluble or insoluble A β , and that they observed a trend with lower levels of soluble A β to be associated with higher levels of KIF5A.

The authors claim that the elevated levels of KIF5A mRNA and KLC1 mRNA in AD brain samples may be a compensatory response to other pathological processes that interfere with axonal transport of protein cargoes to the synapse. The authors found lower KIF5A mRNA levels in SNPs with susceptibility for MS but no changes in protein levels; and lastly the authors found no changes in KLC1 mRNA in the same samples.

Based on all their findings the authors highlight the importance of KIF5A in maintaining axonal transport and raise the possibility that patients with higher “reserve levels” of KIF5A are less susceptible to axonal transport disruption and pathology. Similarly, the authors propose based on their results that genetic polymorphisms within KIF5A gene locus could represent a common neurodegenerative pathway across a spectrum of neurological conditions.

Personal Report:

The experimental evidences provided by Kelly Hares and co-workers, although interesting, are very preliminary and highly speculative. The authors found increased levels of mRNA for KIF5A and KLC1 in AD brain samples but did not observe any effects at protein levels. Interestingly, unlike their previous report, results obtained with a new cohort of AD and control brain samples showed that KIF5A protein levels did not changed between Braak stages 0-II, III-IV or V-VI. Similarly Hares and co-workers did not find any changes in KLC1 or KIF5A protein levels associated to different SNPs within the KIF5A gene locus (rs12368653 and rs4646536) associated with increased susceptibility to AD. Based on these results, this reviewer does not see why the authors emphatically suggest that KIF5A is highly important in maintaining axonal transport, without even analyzing other KIF5s, in particular the neuronal specific KIF5C, as well as KLC2. Recent reports

have determined that functional mutations in KIF5A are associated to different progressive neuropathies, as stated by Hares and co-workers in their manuscript, highlighting the critical role that plays KIF5A in maintaining the transport of important axonal cargoes that otherwise result in pathology. Similarly, it is not evident for this reviewer why the presence of more mRNA for KIF5A (termed "reserve levels" by the authors), which does not result in an increase in KIF5A protein level, will make AD patients less susceptible to axonal transport disruption and pathology. It would be very informative if the authors could propose any particular molecular mechanism to explain such categorical statement. In summary, although preliminary in my opinion, the results obtained by Hares et al. are interesting and promising, however the authors extend too far their discoveries without proposing any particular hypothesis driven mechanism.

References

1. Hares K, Miners JS, Cook AJ, Rice C, et al.: Overexpression of Kinesin Superfamily Motor Proteins in Alzheimer's Disease. *J Alzheimers Dis.* 2017; **60** (4): 1511-1524 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: I work on axonal transport and neurodegeneration.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 17 Jun 2019

Kelly Hares, University of Bristol, Bristol, UK

We thank the reviewer for their comments. On reflection, we agree the conclusions are too

presumptuous and not fully supported by the findings. In light of this, we have amended the manuscript to be less speculative (abstract page 2, discussion page 17) and clarified the hypothesis proposed.

We are pleased the reviewer felt the results are interesting and promising and we feel that the results are of interest to others, irrespective of the fact that we did not show redundancy between KIF5A and KLC-1 as originally hypothesised. We did see significant changes in KIF5A and KLC-1 gene expression and in particular, a rise in KIF5A gene expression at early Braak stages (III-IV). We also saw genotype influenced KIF5A gene expression in AD patients homozygous for a SNP within the KIF5A gene locus that has previously been linked to MS susceptibility. These findings are novel but we agree that they are preliminary and warrant future investigation *in vitro* or *in vivo* for a more comprehensive study of the mechanisms and downstream effects of dysregulated kinesin expression. We have also added this to the discussion (page 17).

We agree with the reviewer that in the context of a larger study, it would be beneficial to analyse the expression of other KIF5 subtypes and KLC2, to strengthen the case for KIF5A as being particularly important in maintaining transport. This point has now been included in the discussion (page 15). We were interested in analysing the relationship between neuronally enriched KIF5A and KLC-1, as they complex together for anterograde axonal transport of several protein cargoes implicated in AD pathology.

We studied neuronally enriched KLC-1 due to genetic polymorphisms within the gene being linked to AD susceptibility (Dhaenens, et al. 2004 and von Otter, et al. 2010), one of which was associated with early AD pathogenesis (Andersson, et al. 2007). To our knowledge there are no known genetic polymorphisms within ubiquitously expressed KLC-2 that are linked to AD. In addition, there is evidence from mouse models to suggest that changes in KLC-1 expression cause axonal swellings and APP/tau accumulation early in AD pathology (Falzone, et al. 2009, Christensen, et al. 2014 and Stokin, et al. 2005). Whereas, to our knowledge, there are no current studies indicating any impact of reduced ubiquitous KLC-2 expression on axonal transport in AD.

Although we appreciate a thorough analysis of all KIF5 members would be interesting for comparison purposes, a large body of evidence implicates KIF5A in human axonopathies. It is only mutations within the KIF5A motor protein that have been linked to diseases such as CMT-2A, SPG10 and ALS (Crimella, et al. 2012 and Brenner, et al. 2008). Moreover, only SNPs within the KIF5A gene locus (not the other KIF5 members) have been linked to MS susceptibility and our previous studies have highlighted changes in neuronally enriched KIF5A within MS human tissue (Hares, et al. 2016). We have an interest in whether SNPs within the KIF5A gene locus are associated with neurodegenerative processes across a range of neurological disorders. Mouse studies have also implicated KIF5A with axonal transport defects but not 5B or 5C (Xia, et al. 2003) and more recently a FAD mouse model has shown reduced levels of KIF5A but not KIF5C (Wang, et al. 2019). In addition, studies in zebrafish have found KIF5A is essential for mitochondrial localisation and transport could not be compensated for by other KIF5 members (Campbell, et al. 2014). Therefore, based on both previous human and animal findings and the unique complexing of KIF5A and KLC-1 for cargo transport, we focused on these two members for the purpose of this study.

We hypothesise that higher levels of KIF5A would mean axonal transport is sustained for longer under stress or disease conditions and that axons would be less likely to form large protein accumulations which can cause Wallerian degeneration and cellular toxicity (we have removed the term 'reserve levels' from the discussion). Others support this hypothesis and have suggested reduced transport of APP by kinesin prolongs exposure of APP to secretases, increases amyloidogenic cleavage and results in A β accumulation in transport vesicles that undergo exocytosis. In addition, reduced kinesin transport of other cargoes that regulate APP proteolysis (Apolipoprotein E receptor 2; ApoER2, calyculin and JNK-associated leucine zipper protein; JLP) can promote A β retention within the secretory pathway (Gan, et al 2014). We have also found significant inverse correlations between KIF5A and APP/dephosphorylated neurofilament in previous studies, which are associated with axonal transection in MS (Hares, et al. 2016).

It is plausible that upregulated KIF5A mRNA expression in AD does not result in higher protein levels due to modification of kinesin metabolism in AD via A β , which could be part of a negative feedback loop between APP transport and processing (Gan, et al. 2014). Recent studies *in vitro* and using FAD mouse models have shown A β reduces KIF5A expression and disrupts KIF5A-mediated mitochondrial transport, which can be rescued by restoration or overexpression of KIF5A (Wang, et al. 2019). This is mentioned in the discussion and has been expanded (Page 15).

Competing Interests: No competing interests were disclosed.